SCHEMBL17601911

SCHEMBL17601911

C=CCN(Cc1cc(=O)oc2c(C=O)c(O)ccc12)C(=O)O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 9/20 0.58
KDM4E B2RXH2 4/20 0.43
MCL1 Q07820 2/20 0.41
APAF1 O14727 1/20 0.39
NSD2 O96028 1/20 0.39
KDM4C Q9H3R0 1/20 0.39
ALDH1A1 P00352 3/20 0.39
GLA P06280 3/20 0.39
HPGD P15428 3/20 0.39
GAA P10253 3/20 0.39
HSD17B10 Q99714 3/20 0.39
CASP1 P29466 2/20 0.39
CASP7 P55210 2/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
MAOB P27338 2/20 0.39
TSHR P16473 1/20 0.38
MAOA P21397 1/20 0.38
GFER P55789 1/20 0.36
CA9 Q16790 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17601908 0.90 ERN1 (0.58) ERN1KDM4EMCL1APAF1NSD2
SCHEMBL17601894 0.81 ERN1 (0.49) ERN1KDM4EMCL1APAF1NSD2
SCHEMBL17601906 0.80 ERN1 (0.47) ERN1KDM4EMCL1APAF1NSD2
SCHEMBL17601923 0.79 LCK (0.59) KDM4EMCL1ALDH1A1GLAHPGD
SCHEMBL17615417 0.77 ERN1 (0.71) ERN1KDM4EMCL1ALDH1A1GLA
SCHEMBL16197973 0.75 ERN1 (0.69) ERN1KDM4EMCL1ALDH1A1GLA
SCHEMBL16197777 0.74 ERN1 (0.70) ERN1KDM4EMCL1ALDH1A1GLA
SCHEMBL17615425 0.73 ERN1 (0.66) ERN1KDM4EMCL1ALDH1A1GLA
SCHEMBL30848799 0.72 ERN1 (1.00) ERN1KDM4EMCL1ALDH1A1GLA
SCHEMBL16208775 0.72 ERN1 (1.00) ERN1KDM4EMCL1ALDH1A1GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10323013-B2 Inhibitors of the IRE-1/XBP-1 pathway and methods of using thereof H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) 2019-06-18 US disclosed
US-20160083361-A1 INHIBITORS OF THE IRE-1/XBP-1 PATHWAY AND METHODS OF USING THEREOF H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. 2016-03-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10323013-B2 Inhibitors of the IRE-1/XBP-1 pathway and methods of using thereof XBP1, ERN1, SREBF1 ERN1 2/4885KDM4E 2963/4885MCL1 6/4885
US-20160083361-A1 INHIBITORS OF THE IRE-1/XBP-1 PATHWAY AND METHODS OF USING THEREOF XBP1, RRP1B, ERN1 ERN1 3/4885KDM4E 3704/4885MCL1 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.